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Abstract
Increasing evidence suggests that inflammation is one pathophysio-logical mechanism in 
Alzheimer's disease (AD). Recent studies have identifiedan association between the poly (ADP-
ribose) polymerase 1 (PARP1) gene and AD. This gene encodes a protein that is involved in many 
biological functions, including DNA repair and chromatin remodeling, and is a mediator of 
inflammation. Therefore, we performed a targeted genetic association analysis to investigate the 
relationship between the PARP1 polymorphisms and brain micro-glial activity as indexed by 
[11C]PBR28 positron emission tomography (PET). Participants were 26 non-Hispanic Caucasians 
in the Indiana Memory and Aging Study (IMAS). PET data were intensity-normalized by injected 
dose/total body weight. Average PBR standardized uptake values (SUV) from 6 bilateral regions 
of interest (thalamus, frontal, parietal, temporal, and cingulate cortices, and whole brain gray 
matter) were used as endophenotypes. Single nucleotide polymorphisms (SNPs) with 20% minor 
allele frequency that were within +/− 20 kb of the PARP1 gene were included in the analyses. 
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Gene-level association analyses were performed using a dominant genetic model with translocator 
protein (18-kDa) (TSPO) genotype, age at PET scan, and gender as covariates. Analyses were 
performed with and without APOE ε4 status as a covariate. Associations with PBR SUVs from 
thalamus and cingulate were significant at corrected p<0.014 and <0.065, respectively. Subsequent 
multi-marker analysis with cingulate PBR SUV showed that individuals with the “C” allele at 
rs6677172 and “A” allele at rs61835377 had higher PBR SUV than individuals without these 
alleles (corrected P<0.03), and individuals with the “G” allele at rs6677172 and “G” allele at 
rs61835377 displayed the opposite trend (corrected P<0.065). A previous study with the same 
cohort showed an inverse relationship between PBR SUV and brain atrophy at a follow-up visit, 
suggesting possible protective effect of microglial activity against cortical atrophy. Interestingly, 
all 6 AD and 2 of 3 LMCI participants in the current analysis had one or more copies of the “GG” 
allele combination, associated with lower cingulate PBR SUV, suggesting that this gene variant 
warrants further investigation.
1 Introduction
Alzheimer's disease (AD) is the most common form of dementia and a progressive, 
degenerative disorder resulting in loss of memory at first, and eventually affecting all 
cognition and behavior. Increasing evidence suggests that failed or dysregulated immune 
response is one candidate mechanism contributing to the pathogenesis of AD [1-4]. Recent 
large-scale genome-wide association studies (GWAS) have identified several candidate 
genetic variants in CLU, CR1, ABCA7, BIN1, PICALM, CD33, CD2AP, EPHA1 and 
MS4A6A/MS4A6E in addition to the most robust candidate gene, APOE [5-8]. Several of 
these genes are known to be involved in immune system functioning [2, 3].
The poly (ADP-ribose) polymerase 1 (PARP1) gene plays roles in many biological functions 
including chromatin remodeling, DNA repair, telomere maintenance and others and is 
known to be a mediator of inflammation via regulation of NF-κB and other transcription 
factors [9]. Several studies have investigated the PARP1 gene in relation to AD [9-12] 
reporting risk and protective haplotypes [10], enhanced activity of PARP1 in AD brain [12], 
and association with rate of hippocampal atrophy [11].
The peripheral benzodiazepine receptor (PBR; official name – translocator protein (18kDa), 
TSPO) is expressed at low levels in relatively inactive microglia. Microglia play an early 
critical role in activation of the immune response in the central nervous system [13]. 
Because activated microglia express higher levels of PBR than inactive microglia, PBR has 
been considered a useful marker to detect neuroinflammation. Positron emission 
tomography (PET) imaging of the N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-
pyridinamine ([11C]PBR28) radioligand has shown high specific signal for microglial 
activity in vivo [14]. The goal of this study was to investigate the relationship between 
PARP1 gene variation and microglial activity indexed by [11C]PBR28 PET.
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2 Materials and Methods
2.1 Participants
In order to reduce the potential bias of population stratification, analyses were restricted to 
26 non-Hispanic Caucasian participants from the Indiana Memory and Aging Study (IMAS) 
cohort. IMAS is an ongoing longitudinal study, including euthymic older adults with 
subjective cognitive decline (SCD) including memory concerns (e.g., self-perceived decline) 
in the context of cognitive test performance that is within the normal range, patients with 
early and late amnestic mild cognitive impairment (EMCI and LMCI) or mild AD, and age-
matched cognitively normal controls (NC) without significant cognitive complaints or 
concerns. Details regarding participant selection criteria and characterization have been 
described previously [15, 16]. This study was approved by the institutional review board and 
written informed consent was obtained from all participants. The 26 participants in the study 
included 7 NC, 6 CC, 4 EMCI, 3 LMCI, and 6 AD. Table 1 shows the sample 
characteristics. APOE ε2/ε3/ε4 genotype, genome-wide genotyping data, and [11C]PBR28 
PET scans were available for all participants. It has been shown that the rs6971 variant in 
the TSPO gene affects in vivo binding affinity of the [11C]PBR28 ligand [17, 18]. Samples 
with mixed or high affinity at the TSPO were included in the study; one non-binder was 
excluded.
2.2 Data and quality control procedure
Genetic data—Genotyping was performed on genomic DNA from blood using the 
Illumina HumanOmniExpress BeadChip (Illumina, Inc., San Diego, CA), which contains 
over 700,000 SNP (single nucleotide polymorphism) markers, according to the 
manufacturer's protocols (Infinium HD Assay; Super Protocol Guide; Rev. A, May 2008). 
APOE ε2/ε3/ε4 genotyping was separately performed. All genotype data, including two 
APOE SNPs (rs429358 and rs7412), underwent standard quality control (QC) assessment 
using PLINK v1.07 [19] as described previously [20]. SNPs were imputed using the 1000 
Genomes reference panel (http://www.1000genomes.org/) following the Enhancing 
Neuroimaging Genetics through Meta-Analysis 2 (ENIGMA 2) imputation protocol (http://
enigma.loni.ucla.edu/wp-content/uploads/2012/07/ENIGMA2_1KGP_v3.pdf [27 July 
2012]). Some imputed SNPs were removed based on the following criteria: r2 < 0.5 between 
imputed and the nearest genotyped SNPs. After all QC steps, 96 SNPs with 20% minor 
allele frequency that were within +/− 20 kb of the PARP1 gene were included in the 
analyses.
Imaging data—Dynamic PET scans, acquired on a Siemens HR+, were initiated with 
injection of ~555 MBq of [11C]PBR28. Data were acquired for 90 min (10x30s, 9x60s, 
2x180s, 8x300s, 3x600s). PET data were processed as described previously [18]. In brief, 
PET data were motion-corrected and normalized to MNI space. Static images were created 
from data between 40-90 min, and were normalized by injected dose/total body weight to 
produce standardized uptake value (SUV) images. Regions of interest (ROIs) were 
generated from each subject's anatomic MRI, which was concurrently acquired on a Siemens 
Tim Trio using an MPRAGE sequence and post processed using Freesurfer v4.0.1 (http://
surfer.nmr.mgh.harvard.edu/). Average [11C]PBR28 SUV values were extracted from 6 
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bilateral ROIs (thalamus, frontal, parietal, temporal, and cingulate cortices, and whole brain 
gray matter including cingulate and sensory motor areas) and used as endophenotypes.
2.3 Statistical analyses
In order to investigate the overall influence of PARP1 variants on microglial activity 
indexed by average [11C]PBR28 SUV values in 6 bilateral ROIs, a set-based analysis 
method in PLINK was adopted. In brief, this method evaluates the association of individual 
SNPs in a given set with a given phenotype and selects a set of independent (based on r2 
threshold) and significant (based on p threshold) SNPs to represent the overall effect of the 
set. Then, the significance of the overall set effect is assessed using permutation to correct 
for multiple SNPs within a set while taking into account the linkage disequilibrium (LD) 
structure among SNPs. In this study, the analysis was performed using the following 
settings: (1) r2 threshold: 0.3, (2) p threshold: 0.05, (3) maximum number of independent 
and significant SNPs: 99999 in order to use all independent and significant SNPs, and (4) 
number of permutation: 50,000. Due to the limited number of samples, only a dominant 
genetic model was assessed. Age at PET scan, gender and TSPO binding affinity based on 
rs6971 genotype were added to the model as covariates. Analysis was performed with and 
without APOE ε4 status as a covariate.
When more than one independent and significant SNP were identified from significant 
associations, a subsequent multi-marker analysis was performed using a haplo-type analysis 
method in PLINK with the same set of covariates in the model. The association p-value was 
corrected for multiple testing (the number of SNP combinations) using 50,000 permutations. 
Although the PLINK set-based approach provides the significance of the PARP1 gene and 
the list of independent and significant SNPs in PARP1, it does not show the joint influence 
of multiple SNPs on average [11C]PBR28 SUV values. This multi-marker method allowed 
us to further study the combinatorial effect of multiple SNPs on average [11C]PBR28 SUV 
values.
3 Results
PARP1 variation was associated with average PBR SUV from thalamus at p<0.014 after 
adjusting for APOE ε4 status. This association was driven by rs874583, located in the 
intergenic area downstream of the gene. Samples with one or more minor allele (“C”) of 
rs874583 showed higher SUV in thalamus (Fig.1). Another association with average PBR 
SUV in cingulate showed marginal significance at p<0.065 after APOE ε4 adjustment and 
was driven by two SNPs (rs6677172 and rs61835377). Both SNPs are intergenic and 
downstream of the gene. Minor alleles of these two SNPs (rs6677172: “G”, rs61835377: 
“A”) showed an inverse relationship with average PBR SUV in cingulate.
Two SNPs (rs6677172 and rs61835377) ere jointly associated with average PBR SUV in 
cingulate. Therefore, a subsequent multi-marker analysis was performed to investigate 
influence of the allele combination of the SNPs on the same phenotype. The analysis 
identified three different combinations of alleles (“CA”,”CG”, and “GG”), of which two 
were significantly associated with average PBR SUV in cingulate at uncorrected p<0.05. 
One (“CA”) was significant after correction for multiple testing at corrected p<0.05. Table 2 
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summarizes the multi-marker analysis results. “CA” allele combination was positively 
correlated with the PBR SUV and “GG” allele combination was negatively correlated with 
the phenotype. Average PBR SUVs in cingulate are displayed in Fig.2 for samples with and 
without “CA” allele combination (Fig.2 (a)) and with and without “GG” allele combination 
(Fig.2 (b)). Interestingly, all 6 AD and 2 out of 3 LMCI participants in the current analysis 
had one or two copies of the “GG” allele combination, associated with lower average 
cingulate PBR SUV.
4 Conclusions
This preliminary study investigated the relationship between variation in PARP1 and 
microglial activity indexed by [11C]PBR PET and identified significant associations of the 
gene with average PBR SUVs in thalamus and cingulate. The subsequent multi-marker 
analysis also identified two allele combinations from the gene-based analysis associated 
with average PBR SUV in cingulate. These identified associations confirmed the role of 
PARP1 in immune activation. Microglia can perform different functions [1, 13] and the 
specific role in the current sample of older adults at risk for AD is not known and may 
include both adaptive and adverse aspects. However, one interesting observation in the 
current study is that 8 out of 9 participants with AD or LMCI had one or two copies of the 
“GG” allele combination, which was associated with lower average PBR SUV in cingulate 
compared to non-“GG” carriers. A previous study with the same cohort showed an inverse 
relationship between PBR SUV and brain atrophy at a follow-up visit, suggesting a possible 
protective effect of microglial activity against cortical atrophy [21], which warrants further 
investigation. A major limitation of this preliminary study is the modest sample size which 
attenuates power and the findings require replication in larger, independent samples as a 
future direction. The relationship between PARP1 and microglial activity also warrants 
experimental molecular validation. Despite the limited sample size, this preliminary study 
identified interesting significant in vivo associations in an important pathway related to AD 
pathobiology. This approach combining neuroimaging and genetics data appears promising 
and can be applied to many related fields of research.
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Average [11C]PBR SUV in thalamus in PARP1 variant, rs874583 (minor allele: C). SUV 
was adjusted for age at PET scan, gender, TSPO binding affinity, and APOE ε4 status. The 
horizontal bars represent the mean PBR SUV for each genotype group.
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Scatter plots of average PBR SUV in cingulate for (a) “CA” allele group and (b) “GG” allele 
group. Average PBR SUV was adjusted for age at PET scan, gender, TSPO binding affinity, 
and APOE ε4 status. The horizontal bars represent the mean PBR SUV for each allele group.
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Table 1
Sample Characteristics
Characteristics All NC SCD EMCI LMCI AD
Number of Samples 26 7 6 4 3 6
Age at PET scan (years; mean±SD) 71.3±7.49 68.4±2.64 70.3±9.81 74.5±6.95 72.7±5.69 72.7±10.48
Education (years; mean±SD) 16.4±2.78 16.3±1.70 17.3±1.21 15.5±4.12 15.3±3.06 16.5±4.18
Gender (M/F) 9/17 1/6 2/4 2/2 2/1 2/4
APOE (ε4−/ε4+) 15/11 3/4 4/2 3/1 2/1 3/3
TSPO binding affinity (Mixed/High) 9/17 2/5 1/5 3/1 2/1 1/5
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Table 2
Multi-marker analysis results. Allele, F, BETA, P, and Corrected P represent allele combination, frequency of 
allele combination, regression coefficient, uncorrected p, and corrected p for the number of allele combination, 
respectively.
PHENOTYPE Allele F BETA P Corrected P
Average PBR SUV Cingulate CA 0.212 0.204 0.0105 0.02962
GG 0.385 −0.164 0.0241 0.06426
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